 |
    | | ||
 |
 | |||
 |
|
 | ||
 | ||||
|
|
  Cytomedix develops biologically active regenerative therapies for wound care, angiogenesis, and inflammation. Our goal is to harness the complex balance of essential life processes, functions and activities that mirror the potent therapeutic effects of the human body, to treat complex medical conditions. Read more about our company.  Cytomedix CEO Issues Shareholder Update Cytomedix, Inc. Reports Year-End 2008 Financial Results “Martin Rosendale, Cytomedix CEO, was recently a featured guest on the Leaders Spot with Rebecca Blacksmith. During the interview Mr. Rosendale discusses his leadership styles and philosophies for leading Cytomedix, as well as the challenges and successes of the AutoloGel System” To listen to the full interview click on the link. Read all press releases.  The AutoloGel System harnesses the patient's natural healing processes with the delivery of a platelet releasate gel containing growth factors, cytokines and chemokines required for cell growth and formation of new tissue. Restoring the balance in the wound environment can transform a non healing wound to a wound that heals naturally. Continue > 
|
| ||
 |
  | |||
| © 2009 Cytomedix. All Rights Reserved. | Site Map | Terms & Conditions |